News

  • Genomic testing for non-small cell lunch cancer under used in community-based practices

    Published on July 17, 2017

    Recommended genomic profiling for EGFR and ALK appeared inconsistent and under used among patients diagnosed with non-small cell lung cancer at community-based practices, according to published findings. Read full article onh healio.com.

  • Significant survival improvement shown by Kyprolis Phase III trial in myeloma

    Published on July 14, 2017

    Significant survival improvement shown by Kyprolis Phase III trial in myeloma US biotech major Amgen announced positive results from the final analysis of the Phase III ASPIRE trial, confirming results of the previous ENDEAVOR study. The study met the key secondary endpoint of overall survival (OS), demonstrating that Kyprolis (carfilzomib), lenalidomide and dexamethasone (KRd) reduced… View Article

  • Cancers Treated with Tomotherapy Dr. Glen Getherman

    Published on

    Cancers Treated with Tomotherapy Dr. Glen Getherman answers questions about Tomotherapy (this recording also aired on 1010WINS) Read full article on hackensackmeridianhealth.org.

  • Pacific Coast Business Times

    Published on July 13, 2017

    Amgen’s Kyprolis found to increase cancer survival rate A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when… View Article

  • Carfilzomib Combo Extends Survival for Myeloma in Final ASPIRE Analysis

    Published on

    The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21 percent compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma following prior treatment with one to three regimens, according to the final analysis of the phase III ASPIRE trial. “For multiple myeloma patients, the first relapse… View Article

  • JTCC and MedStar Georgetown University Hospital Announce 100th Blood Stem Cell Transplant

    Published on June 24, 2017

    MedStar in collaboration with John Theurer Cancer Center announce 100th blood stem cell transplant since the BMT program’s first patient was treated in September, 2013. Read full article on burrellesluce.com.

  • NJBIZ names the Healthcare Heroes award winners

    Published on June 21, 2017

    Andre Goy, M.D., chairman and Lymphoma Division chief, John Theurer Cancer Center; chief science officer, Regional Cancer Care Associates; chair of Oncology, Seton Hall-Hackensack Meridian School of Medicine; professor of medicine, Georgetown University receives Education Hero (Individual) recognition from NJBIZ. Read full article on njbiz.com.

  • Wyckoff YMCA hosts Bourbon and Bling fundraiser

    Published on June 20, 2017

    Wyckoff YMCA held a Bourbon and Bling reception in memory of Wyckoff resident Robert J. Kane, Esq. The evening included dinner, a bourbon bar, specialty cocktails, raffles, as well as auctions with 100% of proceeds donated to the John Theurer Cancer Center at Hackensack University Medical Center. Read full article on northjersey.com.

  • Andrew Pecora, M.D. Awarded Rosemarie J. Sorce Endowed Chair in Innovation $2 million grant will further Dr. Pecora’s work in cancer research

    Published on June 14, 2017

    Dr. Pecora received the Rosemarie J. Sorce Endowed Chair in Innovation at Hackensack Meridian Health. The award is in honor of his lifetime achievements in medicine, including cancer research and treatment. Read full article on COUNTY SEAT.

  • Late Essex County surgeon receives posthumous honor

    Published on

    Hackensack Meridian Health finalists featured on the Healthcare Heroes list include Dr. Andre Goy, chairman of the John Theurer Cancer Center at Hackensack University Medical Center. Goy was named an Education Hero Finalist. Read full article on Record/NorthJersey.com.

  • HMH to Pilot Combined Watson for Oncology and COTA Technology to Power Value-Based Clinical Decision Support in Cancer Care

    Published on June 13, 2017

    IBM, Cota and HMH announced a collaboration to pilot a combination of IMB Watson and Cota technology for the first time. The goal is to bring Cota’s value-based care and real-world data into IBM’s Watson for Oncology clinical decision support tool, which HMH oncologists will then use in a pilot to inform patient care. Read… View Article

  • Can Flatiron Health redeem EHRs?

    Published on June 11, 2017

    Dr. Pecora discusses Flatiron Health’s OncoEMR platform – Instead of building an EHR, Cota uses its technologies to focus on delivering precision medicine. The company “patented a Real World Data classification system — the Cota Nodal Address System — that captures, validates and structures all prognostically relevant attributes of a patient, their disease and therapy…. View Article